Although, long term use of IFN-β therapy is associated with both increased KYN/TRP ratios (reflecting higher KP activity) (Amirkhani et al., 2005) and stability of depression in MS (Arnett and Randolph, 2006). The gene discussed is NPPA; the disease is depressive symptom measurement.